

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

03 FEB 14 PM 1:

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Merck &amp; Co., Inc.</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889-0100</u>			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID # <u>24908-12</u>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30)  OR Year End (July 1-Decen

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_

11. No Lobbying /

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ <u>4,670,294.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate the accounting method. See instructions for description of:</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(c) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
--	--

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Merck & Co., Inc. Client Name \_\_\_\_\_ Self \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page) (Budget/Appropriations)

16. Specific lobbying issues

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above.  Check if None



Signature Jon Filderman Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel

Form LD-2(Rev.6/98)

Page

Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CAW (one per page) (Clean Air & Water)

16. Specific lobbying issues

None 17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page) (Copyright/Patent/Trademark)

16. Specific lobbying issues

Oppose S.812, Greater Access to Affordable Pharmaceutical Act of 2001.


17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Nancy Carlton	Vice President, Government Relations
Stacey Rampy	Director & Counsel, Government Relations
Laurie Michel	Sr. Director & Counsel, Government Relations
Victoria Blatter	Sr. Director, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific lobbying issues

None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Fildeman, Corporate Counsel

Form I D-2(Rev 6/98)

Page

Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code DIS (one per page) (Disaster Planning/Emergencies)


16. Specific lobbying issues

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page) (Environmental/Superfund)

16. Specific lobbying issues

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page) (Health Issues)

16. Specific lobbying issues

Support H.R. 4954, Medicare Modernization and Prescription Drug Act of 2002.

Oppose repeal or modification of Sections 1714-1717 of Homeland Security Act of 2002 (H.R.5005)

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Nancy Carlton	Vice President, Government Relations
Ian Spatz	Executive Director, Public Policy
Victoria Blatter	Sr. Director, Government Relations
Stacey Rampy	Director & Counsel, Government Relations
Cynthia Smith	Director, Public Policy
Laurie Michel	Sr. Director & Counsel, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel

Form I.D. 2 (Rev. 6/08)

Page

Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code IMM (one per page)

16. Specific lobbying issues

None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific lobbying issues

None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

9. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MAN (one per page)

16. Specific lobbying issues

None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel

Form LD-2(Rev 6/98)

Page

Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page) (Medical/disease Research/Clinical labs)

16. Specific lobbying issues

Medical records confidentiality.  
Support efforts to modify HIPAA Privacy Regulation through NPRM process.

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate  
Department of Health & Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Laurie Michel	Senior Director & Counsel, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel

Form LD-2(Rev.6/98)

Page

Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page) (Medicare/Medicaid)

16. Specific lobbying issues

Support H.R. 4954, Medicare Modernization and Prescription Drug Act Of 2002.

Oppose Stabenow amendment (SA 4305) to S.812, Greater Access to Affordable Pharmaceuticals Act of 2007

Support Grassley amendment (SA 4310) to S.812.

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Nancy Carlton	Vice President, Government Relations
Victoria Blatter	Sr. Director, Government Relations
Ian Spatz	Executive Director, Public Policy
Stacey Rampy	Director & Counsel, Government relations
Laurie Michel	Dr. Director & Counsel, Government Relations
Cynthia Smith	Director, Public Policy

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None



Signature *J. Filderman* Date February 10, 2006

Printed Name and Title Jon Filderman, Corporate Counsel

Form LD-2(Rev.6/98)

Page

Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page) (Science/Technology)

16. Specific lobbying issues


None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page) (Taxation/Internal Revenue Code)

16. Specific lobbying issues

None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel



Registrant Name. Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page) (Trade-Domestic/Foreign)

16. Specific lobbying issues

Oppose Dorgan amendment (SA 4299) to S.812, the Greater Access to Affordable Pharmaceuticals Act of 2003 (pharmaceutical importation)


17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate  
Department of State

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Laurie Michel	Sr. Director & Counsel, Government Relations
Stacey Rampy	Director & Counsel, Government Relations
Victoria Blatter	Sr. Director, Government Relations
Nancy Carlton	Vice President, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code VET (one per page)

16. Specific lobbying issues

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel



Registrant Name Merck & Co., Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code WAS (one per page) (Waste-Hazardous/Solid/Interstate/Nuclear)

16. Specific lobbying issues


None

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date February 13, 2003

Printed Name and Title Jon Filderman, Corporate Counsel

